Table 1.
Clinical trials testing proteasome inhibitors in GBM.
| No. | Trial Phase | Number of Patients | Tumor Type/Status | Treatment Investigated | Year of the Publication | Trial #No. d, Publication |
|---|---|---|---|---|---|---|
| 1. | I | 19 a | Newly diagnosed and recurrent GBM b | Bortezomib (dose escalation study), RT, TMZ | 2009 | [47] |
| 2. | I | 51 b | Recurrent GBM | Bortezomib (dose escalation study), EIASDs | 2010 | [48] |
| 3. | II | 37 | Recurrent GBM | Bortezomib, Vorinostat | 2011 | [42] |
| 4. | I | 25 c | Solid tumors | Bortezomib, TMZ, HEIA’s | 2012 | [49] |
| 5. | II | 10 | Recurrent GBM | Bortezomib, TMZ | 2016 | [32] |
| 6. | II | 24 | Newly diagnosed GBM | Bortezomib, RT, TMZ | 2018 | NCT00998010, ref. [50] |
| 7. | I/II | 10 | Recurrent GBM | Bortezomib, TMZ | 2020 | NCT03643549, ref. [39] |
| 8. | I/II | 30 | Recurrent GBM | Marizomib (dose escalation study) | 2021 | NCT02330562, ref. [43] |
| 9. | I/II | 67 | Recurrent GBM | Marizomib, Bevacizumab | 2021 | NCT02330562, ref. [43] |
| 10. | III | 749 | Newly diagnosed GBM | Marizomib, RT, TMZ | 2021 | NCT03345095, ref. [51] |
a Number of patients diagnosed with GBM, including 11 patients with newly diagnosed GBM and 8 patients with recurrent GBM; b out of 66 patients enrolled in the study, 51 had a diagnosis of recurrent GBM; c out of 25 patients enrolled, 2 received a high-grade glioma diagnosis; d for earlier trials, NCT numbers are not specified.